Roman Butler Fullerton & Co’s Neurocrine Biosciences NBIX Stock Holding History

Roman Butler Fullerton & Co’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$374K	Buy	+2,150	New	+$319K	0.09%	211
2024 Q1	–	Sell	-8,837	Closed	-$1.26M	–	217
2023 Q4	$1.26M	Buy	+8,837	New	+$1.02M	0.49%	54
2023 Q1	–	Sell	-11,864	Closed	-$1.28M	–	201
2022 Q4	$1.28M	Buy	11,864 +1,305	+12%	+$153K	0.66%	46
2022 Q3	$1.14M	Buy	+10,559	New	+$1.07M	0.72%	36
2020 Q3	–	Sell	-7,422	Closed	-$905K	–	159
2020 Q2	$905K	Buy	+7,422	New	+$820K	0.65%	54

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Roman Butler Fullerton & Co's NBIX Position: Q2 2026 in Review

Roman Butler Fullerton & Co opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 2,150 shares worth $374K. The stake represents 0.09% of the portfolio and ranks #211 among its holdings. This is a return to the name: Roman Butler Fullerton & Co previously reported a position in NBIX as recently as Q4 2023.

Roman Butler Fullerton & Co first reported a position in NBIX in Q2 2020 and has held it in 5 quarters since. The position peaked at $1.28M in Q4 2022. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Roman Butler Fullerton & Co held 2,150 shares of Neurocrine Biosciences worth $374K as of Q2 2026.
Neurocrine Biosciences was a new Roman Butler Fullerton & Co position in Q2 2026.
Neurocrine Biosciences made up 0.09% of Roman Butler Fullerton & Co's portfolio in Q2 2026, its #211 holding.
Roman Butler Fullerton & Co first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 5 quarters since.
Roman Butler Fullerton & Co's Neurocrine Biosciences position peaked at $1.28M in Q4 2022.
779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Roman Butler Fullerton & Co's 13F filing for Q2 2026, filed 6 Aug 2026.